BUSINESSTECHCRUNCH
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Colossal Biosciences, a de-extinction startup, is reportedly in talks to raise new capital with a valuation range of $20B–$30B, aiming to double or triple its previous valuation.
Related Signal
Adjacent reporting
- Funding option: royalties giant opens Hong Kong base as mainland China biotech deals surge
- Funding option: royalties giant opens Hong Kong base as mainland China biotech deals surge
- Ramp in talks to hit $40B+ valuation, 6 months after reaching $32B
- Kalshi in talks to raise funds at $40 billion valuation: FT
- Kalshi seeks funding at $40B valuation, nearly doubling last raise: FT
- Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO